MENU
+Compare
CAPR
Stock ticker: NASDAQ
AS OF
May 30 closing price
Price
$9.89
Change
-$0.20 (-1.98%)
Capitalization
452.05M

CAPR stock forecast, quote, news & analysis

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs... Show more

Industry: #Biotechnology
CAPR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for CAPR with price predictions
May 30, 2025

CAPR's RSI Oscillator recovers from oversold territory

The RSI Indicator for CAPR moved out of oversold territory on May 13, 2025. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 31 similar instances when the indicator left oversold territory. In of the 31 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on May 19, 2025. You may want to consider a long position or call options on CAPR as a result. In of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for CAPR just turned positive on May 19, 2025. Looking at past instances where CAPR's MACD turned positive, the stock continued to rise in of 39 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CAPR advanced for three days, in of 267 cases, the price rose further within the following month. The odds of a continued upward trend are .

CAPR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 51 cases where CAPR's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

CAPR moved below its 50-day moving average on May 29, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for CAPR crossed bearishly below the 50-day moving average on May 07, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

The 50-day moving average for CAPR moved below the 200-day moving average on April 30, 2025. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CAPR declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CAPR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.541) is normal, around the industry mean (16.282). P/E Ratio (0.000) is within average values for comparable stocks, (59.459). CAPR's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.224). Dividend Yield (0.000) settles around the average of (0.039) among similar stocks. P/S Ratio (22.075) is also within normal values, averaging (270.467).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CAPR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Moderna (NASDAQ:MRNA), Sarepta Therapeutics (NASDAQ:SRPT), BioCryst Pharmaceuticals (NASDAQ:BCRX), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.22B. The market cap for tickers in the group ranges from 151 to 303.58B. NONOF holds the highest valuation in this group at 303.58B. The lowest valued company is MYMX at 151.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 1%. For the same Industry, the average monthly price growth was 0%, and the average quarterly price growth was -5%. SPRO experienced the highest price growth at 259%, while REVB experienced the biggest fall at -65%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -13%. For the same stocks of the Industry, the average monthly volume growth was 60% and the average quarterly volume growth was 139%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 84
Price Growth Rating: 66
SMR Rating: 90
Profit Risk Rating: 95
Seasonality Score: 9 (-100 ... +100)
View a ticker or compare two or three
CAPR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Develops innovative products for the treatment of cardiovascular diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
10865 Road to the Cure
Phone
+1 858 727-1755
Employees
102
Web
https://www.capricor.com